Monte Rosa Therapeutics, Inc. (GLUE) company profile
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
About Monte Rosa Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops molecular glue degraders to selectively eliminate disease-associated proteins using cellular degradation mechanisms. The company designs small molecule therapies across immunology, inflammation, cardiology, and oncology through its proprietary QuEEN discovery platform. Its clinical-stage pipeline includes MRT-6160 for immune-mediated diseases, MRT-8102 for inflammasome-driven inflammatory conditions, and MRT-2359 for metastatic castration-resistant prostate cancer. Because the company currently has no commercial product sales, its primary counterparties are pharmaceutical collaborators, such as Novartis and Roche, which license and develop its drug candidates.
The company maintains research and development operations centered around an internal chemical library that includes more than 1,000 unique scaffolds and over 75,000 distinct molecular glue compounds. Its operational reach and business partnerships include activities in the United States and Switzerland. Monte Rosa Therapeutics is headquartered at its principal executive offices in Boston, Massachusetts.
Summary of the business section of Monte Rosa Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Monte Rosa Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 321 Harrison Avenue, Suite 900 02118
- Phone
- (617) 949-2643
- Website
- monterosatx.com
- Employees
- 150, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- GLUE
- Exchange
- Nasdaq
- IPO date
- Jun 25, 2021
- Shares outstanding
- 85M, Jul 31, 2026
- Public float
- $212.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1826457
- CUSIP
- 61225M102
- ISIN
- US61225M1027
- FIGI
- BBG00X2VGZQ3
- Share class FIGI
- BBG00X2VGZR2
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Markus Warmuth | President & CEO, Director | 585,038 |
| Matthew Bowen | Principal Accounting Officer | 25,891 |
| Jennifer Champoux | Chief Operating Officer | 66,722 |
| Sharon Townson | Chief Scientific Officer | 68,245 |
| Filip Janku | Chief Medical Officer | 60,612 |
| Philip Nickson | Chief Business & Legal Officer | 55,000 |
| Edmund Dunn | Principal Accounting Officer | 22,554 |
| Ali Behbahani | Director | 6,707,298 |
| Anthony M. Manning | Director | 0 |
| Christine Siu | Director | – |
| Kimberly Blackwell | Director | – |
| Jan Skvarka | Director | – |
| Andrew N. Schiff | Director | – |
| Eric A. Hughes | Director | – |
| Chandra P. Leo | Director | 10,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Markus Warmuth Chief Executive Officer | $650.00K | $910.08K | $3.04M | $429.00K | – | $5.03M | +106% |
| Filip Janku Chief Medical Officer | $520.00K | $255.96K | $852.22K | $299.60K | $14.00K | $1.94M | +54% |
| Phil Nickson Chief Business and Legal Officer | $520.00K | $255.96K | $852.22K | $299.60K | $14.00K | $1.94M | +51% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 25, 2021
- Offer price
- $19.00
- Securities offered
- 11,700,000
- Gross proceeds
- $222.30M
- Exchange
- Nasdaq
- First trading day
- Jun 24, 2021
- First-day close
- $21.18+11.5%
- Lock-up ends (est.)
- Dec 21, 2021
“The initial public offering price is $19.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 150 full-time employees, of which 71 have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 25, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 21, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?